Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Lymphohistiocytosis, Hemophagocytic

• Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
• L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
• Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)
• A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients
• Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH
• Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis
• Evaluation of the Safety and Efficacy of ELA026 in Patients With Secondary Hemophagocytic Lymphohistiocytosis
• Rituximab Monotherapy for EBV-HLH and CAEBV
• Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers
• L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH
• DEP Combine With PD-1 Antibody as an Initial Treatment for EBV-HLH
• Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH
• Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's or SLE
• A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.
• Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
• Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome
• A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH）
• Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis
• Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH
• Ruxolitinib Combined With Dexamethasone for HLH
• Etoposide in the First-line Treatment of Adult EBV-HLH
• DEP-Ru Regimen as a Salvage Therapy for HLH
• Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
• Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis
• A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHL
• L-DEP as an Initial Treatment for EBV-HLH
• L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis
• Treatment of Familiar Lymphohistiocytosis
• A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome
• Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
• Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
• Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)
• Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
• Immune Disorder HSCT Protocol
• Trial of DA-EPOCH Regimen for NHL With HLH
• Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
• Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis
• Administration of Donor T Cells With the Caspase-9 Suicide Gene
• Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
• Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004
• T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
• Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis
• Stem Cell Transplant for Immunologic or Histiocytic Disorders
• T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
• Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
• Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies